Press releaseGlobe Newswire
Immatics NV
IMTX · NASDAQ
$7.51+$0.46 (+6.52%)TodayMarket closed ·
Prev close $7.05
Latest news
- Press releaseGlobe Newswire
Immatics Announces First Quarter 2026 Financial Results and Business Update
- News
Immatics Earnings Report: Q4 Overview
- News
Immatics Q4 EPS $(0.34) Beats $(0.48) Estimate, Sales $23.005M Beat $12.180M Estimate
- Press releaseGlobe Newswire
Immatics Announces Full Year 2025 Financial Results and Business Update
- Press releaseGlobe Newswire
Immatics Announces Third Quarter 2025 Financial Results and Business Update
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Immatics Announces Second Quarter 2025 Financial Results and Business Update
- Press releaseGlobe Newswire
Immatics Announces First Quarter 2025 Financial Results and Business Update
- Press releaseBusiness Wire
Clear Street Launches Healthcare & Biotechnology Equity Research
- News
Immatics Announced Updated Phase 1B Data On ACTengine IMA203 TCR-T Targeting PRAME In Melanoma Patients And Provided An Update On Upcoming Phase 3 SUPRAME Trial Of IMA203 In Metastatic Melanoma Patients
- Press releaseGlobe Newswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.